This site is intended for health professionals only!

Published on 5 December 2007

Share this story:

Risk assessed for fatal PE post VTE therapy

teaser

A prospective cohort study has estimated the annual risk for fatal PE and disease recurrence in patients who have discontinued anticoagulant therapy.

The study involved 2052 patients with a first episode of symptomatic venous thromboembolism (VTE: 1450 DVT, 310 PE, and 292 DVT and PE) who discontinued anticoagulant therapy. The mean duration of previous anticoagulant therapy was six months and the mean duration of follow-up after discontinuation of treatment was 54 months.

The following data was reported:

* The annual risk for any fatal PE after discontinuation of anticoagulation was 0.49 events (95% CI, 0.36 to 0.64 events) per 100 person-years;

* The annual risk for definite or probable fatal PE after discontinuation of anticoagulation was 0.19 events (0.12 to 0.30 events) per 100 person-years;

*The case-fatality rate of recurrent disease was 9.0% (6.8% to 11.8%) for any fatal PE and 3.8% (2.4% to 5.9%) for definite or probable fatal PE.

The researchers concluded that the risk for fatal PE was 0.19 to 0.49 events per 100 person-years for patients who finished a course of anticoagulant therapy for a first episode of symptomatic VTE, while the case-fatality rate for death from recurrent PE was 4% to 9%.

They acknowledged that their findings were less pertinent to patients with active cancer, permanent immobility, or high-risk thrombophilia. In addition, decision makers should also take into account the rates of fatal PE recurrence and fatal haemorrhage if anticoagulant therapy was continued.

Annals Of Internal Medicine



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine